The 21-gene Oncotype DX Breast Recurrence Score® assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2−) in Early Breast Cancer (EBC). This evidence concerns the gene ESR1 and breast carcinoma.